Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

Core Insights - The article discusses the investment potential of OCUL, highlighting a beneficial long position in its shares by the analyst [1]. Group 1 - The analyst expresses a personal opinion on OCUL's stock performance and potential [1]. - There is no compensation received for the article other than from Seeking Alpha, indicating an independent analysis [1]. - The article does not provide specific investment recommendations or advice [2].